financetom
Business
financetom
/
Business
/
Cerebras aims to deploy AI infrastructure for massive Stargate UAE data centre hub
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cerebras aims to deploy AI infrastructure for massive Stargate UAE data centre hub
Oct 13, 2025 4:48 AM

*

Cerebras aims to deploy AI infrastructure in UAE,

including for

Stargate, CEO says

*

Company plans to file for IPO again "shortly", CEO says

*

Firm aims to grow data centers number to 12-15 in next 6-8

months

By Federico Maccioni

DUBAI, Oct 13 (Reuters) - AI chip startup Cerebras

Systems aims to deploy its infrastructure to the United Arab

Emirates to support the Gulf state's rapidly growing AI sector,

as well as markets in India and Pakistan, CEO Andrew Feldman

told Reuters on Monday.

"I'm very confident that there will be big clusters here of

our gear," including "megawatts worth of equipment" for the

Stargate project, Feldman, referring to the U.S.-UAE agreement

to build the world's largest set of AI data centres outside the

United States.

California-based Cerebras makes high-performance AI chips

and systems designed to speed up the training and deployment of

large AI models, competing with industry leader Nvidia NVDA.O in

the rapidly expanding AI chip market.

Among its largest clients is Abu Dhabi-backed cloud and AI

firm G42, which signed a deal in 2023 to acquire supercomputers

from the startup.

G42's past ties to China have attracted scrutiny in

Washington, due to concerns around Beijing's access to advanced

semiconductors including via third parties such as the UAE,

which has been spending billions of dollars on its AI push,

looking to leverage its strong relations with the U.S. to secure

access to the technology.

Technology giants, including Nvidia ( NVDA ) and OpenAI, are working

with G42 to build the first phase of Stargate UAE, but the deal

has not been finalised amid these security concerns, Reuters

reported, citing sources.

Cerebras-built computers for G42 have so far remained in the

U.S., with Middle East deals requiring export licences from the

Trump administration.

Cerebras this month filed to withdraw its plans for a U.S.

listing, after raising $1.1 billion in a funding round that

valued the company at $8.1 billion.

New investors include 1789 Capital, a fund in which Donald

Trump Jr is a partner.

Feldman said the company will use the proceeds to scale up

manufacturing and finance the new data centres, aiming to grow

to as many as 12 or 15 sites from six over the next months.

Cerebras still intends to go public, Feldman said, adding it

has an "intention to refile it as quickly as we can", without

providing a timeline.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children
BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children
May 26, 2025
08:33 AM EDT, 05/14/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Wednesday that the US Food and Drug Administration has accepted and granted priority review to its new drug application for Orladeyo, or berotralstat, to treat hereditary angioedema in children 2 to 11 years old. The company said the FDA has set a target action date of Sept....
Sernova Biotherapeutics Provides
Sernova Biotherapeutics Provides "Positive" Interim Data From Type 1 Diabetes Cell Pouch Trial
May 26, 2025
08:33 AM EDT, 05/14/2025 (MT Newswires) -- Sernova Biotherapeutics ( SEOVF ) on Wednesday said interim data from its ongoing Phase 1/2 clinical trial in patients with type 1 diabetes (T1D) show a majority of the enrolled patients achieving insulin independence and improved blood sugar control. The clinical trial involved transplanting Sernova's cell pouch with human donor cells or stem-cell...
Aeva Technologies Enters Collaboration, Investment Agreement With Fortune 500 Company
Aeva Technologies Enters Collaboration, Investment Agreement With Fortune 500 Company
May 26, 2025
08:32 AM EDT, 05/14/2025 (MT Newswires) -- Aeva Technologies ( AEVA ) said Wednesday it has entered into a strategic collaboration with an affiliate of a Fortune 500 company to bring its 4D light detection and ranging technology into new industrial and consumer markets. The company will invest up to around $50 million to bring production capacity online for Aeva's...
Copyright 2023-2026 - www.financetom.com All Rights Reserved